The earnings call presented a strong performance with record sales and significant growth in key areas, particularly in the U.S. and international glaucoma franchises. However, there are notable challenges, including market turbulence from regulatory changes and proposed reimbursement reductions that could impact future growth. Overall, the highlights slightly outweigh the lowlights.

Company Guidance

In the second quarter of 2025, Glaukos Corporation reported record consolidated net sales of $124.1 million, a 30% increase on a reported basis or 29% on a constant currency basis compared to the same quarter last year. This sales boost was primarily driven by the growing adoption and utilization of the iDose TR, which generated approximately $31 million in sales, contributing to a 45% year-over-year growth within the U.S. glaucoma franchise. As a result of this strong performance, Glaukos raised its full-year 2025 net sales guidance to a range of $480 million to $486 million, up from the previous range of $475 million to $485 million. The company's international glaucoma franchise also saw record net sales of $31.3 million, reflecting a 20% year-over-year growth on a reported basis and 15% on a constant currency basis. Furthermore, the Corneal Health franchise recorded net sales of $20.6 million, marking a 4% increase. Glaukos is advancing several clinical programs, including the Phase IIb/III clinical program for iDose TREX and the FDA's ongoing NDA review for Epioxa, with a PDUFA date set for October 20, 2025. The company also made strategic investments, including the acquisition of Mobius Therapeutics and purchasing a new building at its Aliso Viejo headquarters, while still managing to grow its cash and equivalents by over $4 million in the quarter.

Record Second Quarter Consolidated Net Sales

Glaukos reported record second quarter consolidated net sales of $124.1 million, a 30% increase on a reported basis and 29% on a constant currency basis compared to the previous year.

U.S. Glaucoma Franchise Growth

The U.S. Glaucoma franchise delivered record second quarter net sales of $72.3 million, growing 45% year-over-year, driven by iDose TR which generated approximately $31 million in sales.

International Glaucoma Franchise Expansion

International net sales reached $31.3 million, marking a 20% year-over-year growth on a reported basis and 15% on a constant currency basis.

Epioxa NDA Review Progress

Important milestones were completed for Epioxa NDA review, with a PDUFA date set for October 20, 2025, potentially offering a breakthrough treatment for keratoconus patients.

Strong Financial Position

Excluding one-time investments, the company grew its cash and equivalents by more than $4 million in the second quarter.

Glaukos (GKOS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GKOS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.26 / -	-0.28	―	―	―
Jul 30, 2025	2025 (Q2)	-0.26 / -0.24	-0.52	53.85% (+0.28)	―
Apr 30, 2025	2025 (Q1)	-0.35 / -0.22	-0.7	68.57% (+0.48)	―
Feb 20, 2025	2024 (Q4)	-0.38 / -0.40	-0.63	36.51% (+0.23)	―
Nov 04, 2024	2024 (Q3)	-0.48 / -0.28	-0.5	44.00% (+0.22)	―
Jul 31, 2024	2024 (Q2)	-0.52 / -0.52	-0.55	5.45% (+0.03)	―
May 01, 2024	2024 (Q1)	-0.58 / -0.70	-0.59	-18.64% (-0.11)	―
Feb 21, 2024	2023 (Q4)	-0.55 / -0.63	-0.53	-18.87% (-0.10)	―
Nov 01, 2023	2023 (Q3)	-0.55 / -0.50	-0.45	-11.11% (-0.05)	―
Aug 02, 2023	2023 (Q2)	-0.56 / -0.55	-0.83	33.73% (+0.28)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GKOS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$94.05	$86.09	-8.46%
Apr 30, 2025	$94.25	$83.54	-11.36%
Feb 20, 2025	$157.36	$125.88	-20.01%
Nov 04, 2024	$131.38	$127.86	-2.68%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Glaukos (GKOS) report earnings?

Glaukos (GKOS) is schdueled to report earning on Oct 29, 2025, After Close (Confirmed).

What is Glaukos (GKOS) earnings time?

Glaukos (GKOS) earnings time is at Oct 29, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is GKOS EPS forecast?

GKOS EPS forecast for the fiscal quarter 2025 (Q3) is -0.26.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing